Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Cara Therapeutics, Inc. on June 15, 2016. The filing details the outcomes of two proposals submitted to security holders for a vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Proposal 1: Election of Directors
Stockholders elected two directors to serve until the 2019 Annual Meeting:
- Dr. Jeffrey L. Ives: 9,580,306 votes For; 4,067,985 votes Withheld; 6,036,363 Broker Non-Votes.
- Mr. Dean Slagel: 5,844,282 votes For; 7,804,009 votes Withheld; 6,036,363 Broker Non-Votes.
Proposal 2: Ratification of Independent Auditor
Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2016:
- Votes For: 17,414,828
- Votes Against: 2,268,122
- Votes Abstain: 1,704
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the results of the shareholder vote.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Note the significant number of votes withheld for Mr. Dean Slagel (7,804,009) compared to votes For (5,844,282), indicating substantial shareholder dissent on this specific nominee.
- Confirm the term end date for the newly elected directors is the 2019 Annual Meeting.
- Verify the engagement of Ernst & Young LLP for the fiscal year ending December 31, 2016.